14 results on '"Seibold J"'
Search Results
2. Nintedanib dose adjustments and adverse events in patients with progressive autoimmune disease-related interstitial lung diseases in the inbuild trial
- Author
-
Volkmann, E., Castellvi, I., Johnson, S., Matteson, E., Distler, J., Seibold, J., Costabel, Ulrich, James, A., Coeck, C., Quaresma, M., and Cottin, V.
- Subjects
Medizin - Published
- 2020
3. OP0115 EFFECT OF NINTEDANIB ON PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED ILDS: FURTHER DATA FROM THE INBUILD TRIAL
- Author
-
Matteson, E., primary, Kelly, C., additional, Distler, J., additional, Hoffmann-Vold, A. M., additional, Seibold, J., additional, Mittoo, S., additional, Distler, O., additional, Dellaripa, P. F., additional, James, A., additional, Schlenker-Herceg, R., additional, Stowasser, S., additional, Quaresma, M., additional, and Flaherty, K. R., additional
- Published
- 2020
- Full Text
- View/download PDF
4. SAT0157 NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL
- Author
-
Volkmann, E., primary, Castellví, I., additional, Johnson, S., additional, Matteson, E., additional, Distler, J., additional, Seibold, J., additional, Costabel, U., additional, James, A., additional, Coeck, C., additional, Quaresma, M., additional, and Cottin, V., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Trial design: how must we move ahead?
- Author
-
Seibold, J. R., Tyndall, A., Furst, D. E., Seibold, J. R., Tyndall, A., and Furst, D. E.
- Abstract
Scleroderma is clinically heterogeneous and a variety of plausible mechanisms of disease have been hypothesized. Recent years have witnessed a significant improvement in overall survival although all of the gains in management have been therapies for specific organ involvement, e.g. renal crisis and pulmonary arterial hypertension. Future studies will rely on improved clinical science, which involves structured validation of proposed measures of outcome; development of a combined response index; and further refinement of specific subsets of disease expression. Immunoablation with stem cell reconstitution is an example of aggressive therapy chosen as appropriate for a particularly severe disease subset and in whom the pilot data are encouraging. Good science and clinical ethics force continued consideration of equipoise between risk and benefit
- Published
- 2017
6. A path to the future in scleroderma
- Author
-
Distler, O., Matucci-Cerinic, M., Müller-Ladner, U., Seibold, J. R., Distler, O., Matucci-Cerinic, M., Müller-Ladner, U., and Seibold, J. R.
- Published
- 2017
7. Primäre monosymptomatische Enuresis
- Author
-
Seibold, J., primary, Alloussi, S., additional, Todenhöfer, T., additional, Stenzl, A., additional, and Schwentner, C., additional
- Published
- 2015
- Full Text
- View/download PDF
8. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo‐Controlled Trials
- Author
-
Namas, Rajaie, Tashkin, Donald P., Furst, Daniel E., Wilhalme, Holly, Tseng, Chi‐Hong, Roth, Michael D., Kafaja, Suzanne, Volkmann, Elizabeth, Clements, Philip J., Khanna, Dinesh, Elashoff, R., Goldin, J., Roth, M., Furst, D., Bulpitt, K., Chung, W.‐L. J., Viasco, S., Sterz, M., Woolcock, L., Yan, X., Ho, J., Vasunilashorn, S., Costa, I., Seibold, J. R., Riley, D. J., Amorosa, J. K., Hsu, V. M., McCloskey, D. A., Wilson, J. E., Varga, J., Schraufnagel, D., Wilbur, A., Lapota, D., Arami, S., Cole‐Saffold, P., Simms, R., Theodore, A., Clarke, P., Korn, J., Tobin, K., Nuite, M., Silver, R., Bolster, M., Strange, C., Schabel, S., Smith, E., Arnold, J., Caldwell, K., Bonner, M., Wise, R., Wigley, F., White, B., Hummers, L., Bohlman, M., Polito, A., Leatherman, G., Forbes, E., Daniel, M., Martin, D., Steen, V., Read, C., Cooper, C., Wheaton, S., Carey, A., Ortiz, A., Mayes, M., Parsley, E., Oldham, S., Filemon, T., Jordan, S., Perry, M., Connolly, K., Golden, J., Wolters, P., Webb, R., Davis, J., Antolos, C., Maynetto, C., Fessler, B., Olman, M., Sanders, C., Heck, L., Parkhill, T., Rothfield, N., Metersky, M., Cobb, R., Aberles, M., Ingenito, F., Breen, E., Mayes, M., Mubarak, K., Granda, J. L., Silva, J., Injic, Z., Alexander, R., Furst, D., Springmeyer, S., Kirkland, S., Molitor, J., Hinke, R., Mondt, A., Thompson, T., Rounds, S., Weinstein, M., Thompson, B., Paulus, H., Levy, S., Kissin, E., Cheong, F.Y., Marlis, G., Mason‐Berry, J., Saffold, P., Rodriguez, M., Guzman, L., Brook, J., Ibrahim, G., Largaespada, K., Fridley, C., Zulmastashvili, M., Manu, A., Moore, S., Hummers, L., Leatherman, G., Hant, F. N., Gibson, K., Morrison, M., Donnelly, H., Marlin, C., Gangar, J., McCloskey, D. A., Eller, A., Leong, D., Lalosh, M., Obata, J., Arami, S., Franklin, D., Schiopu, E., Benedict‐Blue, M., Leone, V., Shaw, J., Tan, F., Perry, M., Anderson, J., Saulino, A., Carey, P., Esplin, M., and Carlson, P.
- Abstract
To assess the efficacy of mycophenolate mofetil (MMF) and cyclophosphamide (CYC) on modified Rodnan skin score (MRSS) in participants enrolled in the Scleroderma Lung Study (SLS) I and II. SLSI participants received daily oral CYCor matching placebo for 1 year, whereas SLS IIparticipants received daily MMFfor 2 years or daily oral CYCfor 1 year followed by placebo for second year. We assessed the impact of MMFand CYCon the MRSSin SLS IIover a 24‐month period. We also compared the change in MRSSin patients with diffuse cutaneous systemic sclerosis (dcSSc) assigned to CYCand MMFin SLS IIand SLSI versus placebo in SLSI over a 24‐month period using a linear mixed model. In SLS II, the baseline mean ± SD MRSSwas 14.0 ± 10.6 units for CYCand 15.3 ± 10.4 units for MMF; 58.5% were classified as dcSSc. CYCand MMFwere associated with statistically significant improvements in MRSSfrom baseline over the period of 24 months in dcSSc (P< 0.05 at each time point), but there were no differences between the 2 groups. In the dcSSc subgroup, the change in MRSSfrom baseline to all 6‐month visits was similar in SLS IIgroups (MMF,CYC, pooled cohort [MMF+ CYC]) and in the SLSI CYCgroup and showed statistically significant improvements compared to SLSI placebo at 12, 18, and 24 months (P< 0.05). In SLS II,MMFand CYCtreatment resulted in improvements in MRSSin patients with dcSSc over 24 months. In addition, MMFand CYCtreatment resulted in statistically significant improvements in MRSSin patients with dcSSc when compared with the SLSI placebo group.
- Published
- 2018
- Full Text
- View/download PDF
9. Safe long-term therapy of Cushing's syndrome over 37 years with mitotane.
- Author
-
Seibold J, Hönemann M, Tönjes A, and Sandner B
- Subjects
- Female, Pregnancy, Humans, Mitotane therapeutic use, Cushing Syndrome drug therapy, Pituitary ACTH Hypersecretion, Drug-Related Side Effects and Adverse Reactions
- Abstract
While suggested, surgery is not always possible as a first-line treatment of Cushing's Disease (CD). In such cases, patients require medical therapy in order to prevent complications resulting from hypercortisolism. Although there has been a wide expansion in pharmacological options in recent years, mitotane was the agent of choice for treating hypercortisolism decades ago. Due to the introduction of other therapies, long-term experience with mitotane remains limited. Here, we report the case of a woman with CD who was treated with mitotane for 37 years. During the treatment period, biochemical and clinical disease control was achieved and the patient had two uncomplicated pregnancies. Drug-related side effects remained moderate and could be controlled by several dose adjustments. Our case highlights the ability of mitotane to allow an effective control of hypercortisolism and to represent a safe treatment option in special situations where CD requires an alternative therapeutic approach. Furthermore, we provide a literature review of the long-term use of mitotane and reported cases of pregnancy in the context of mitotane therapy., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Seibold, Hönemann, Tönjes and Sandner.)
- Published
- 2024
- Full Text
- View/download PDF
10. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
- Author
-
Roofeh D, Barratt SL, Wells AU, Kawano-Dourado L, Tashkin D, Strand V, Seibold J, Proudman S, Brown KK, Dellaripa PF, Doyle T, Leonard T, Matteson EL, Oddis CV, Solomon JJ, Sparks JA, Vassallo R, Maxwell L, Beaton D, Christensen R, Townsend W, and Khanna D
- Subjects
- Humans, Lung, Reproducibility of Results, Respiratory Function Tests, Lung Diseases, Interstitial complications, Scleroderma, Systemic complications
- Abstract
Objective: The Outcome Measures in Rheumatology (OMERACT) is a research organization focused on improving health care outcomes for patients with autoimmune and musculoskeletal diseases. The Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) Working Group on Lung Physiology is a group within OMERACT charged with identifying outcome measures that should be implemented in studies of patients with CTD-ILD. The OMERACT Filter 2.1 is an evidence-based algorithm used to identify outcome measures that are truthful, feasible, and able to discriminate between groups of interest. Our objective was to summate evidence (published literature, key opinion leader input, patient perspectives) that would influence the CTD-ILD Working Group's vote to accept or reject the use of two measures of lung physiology, the forced vital capacity (FVC) and the diffusion capacity of carbon monoxide (DLco) for use in randomized controlled trials (RTCs) and longitudinal observational studies (LOSs) involving patients with systemic sclerosis associated ILD (SSc-ILD)., Methods: Patient Research Partners (those afflicted with SSc-ILD) and the CTD-ILD Working Group on Lung Physiology were polled to assess their opinion on the FVC and DLco in terms of feasibility; the CTD-ILD Working Group was also queried on these instruments' face and content validity. We then conducted a systematic literature review to identify articles in the SSc-ILD population that assessed the following measurement properties of FVC and DLco: (1) construct validity, (2) test-retest reliability, (3) longitudinal construct validity, (4) clinical trial discrimination/sensitivity to detect change in clinical trials, and (5) thresholds of meaning. Results were summarized in a Summary of Measurement Properties (SOMP) table for each instrument. OMERACT CTD-ILD Working Group members discussed and voted on the strength of evidence supporting these two instruments and voted to endorse, provisionally endorse, or not endorse either instrument., Results: Forty Patient Research Partners reported these two measures are feasible (are not an unnecessary burden or represent an infeasible longitudinal assessment of their disease). A majority of the 18 CTD-ILD Working Group members voted that both the FVC and DLco are feasible and have face and content validity. The systematic literature review returned 1,447 non-duplicated articles, of which 177 met eligibility for full text review. Forty-eight studies (13 RCTs, 35 LOSs) were included in the qualitative analysis. The FVC SOMP table revealed high quality, consistent data with evidence of good performance for all five measurement properties, suggesting requisite published evidence to proceed with endorsement. The DLco SOMP table showed a lack of data to support test-retest reliability and inadequate evidence to support clinical trial discrimination. There was unanimous agreement (15 [100%]) among voting CTD-ILD Working Group members to endorse the FVC as an instrument for lung physiology in RCTs and LOSs in SSc-ILD. Based on currently available evidence, DLco did not meet the OMERACT criteria and is not recommended for use in RCTs to represent lung physiology of SSc-ILD. The OMERACT Technical Advisory Group agreed with these decisions., Conclusion: The OMERACT Filter 2.1 was successfully applied to the domain of lung physiology in patients with SSc-ILD. The FVC was endorsed for use in RCTs and LOSs based on the Working Group's vote; DLco was not endorsed., Competing Interests: Declaration of Competing Interest Please see each author's ICJME form., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
11. Intentional switching in auditory selective attention: Exploring attention shifts with different reverberation times.
- Author
-
Oberem J, Seibold J, Koch I, and Fels J
- Subjects
- Adult, Audiometry, Pure-Tone, Audiometry, Speech, Auditory Threshold, Female, Hearing, Humans, Male, Motion, Photic Stimulation, Psychoacoustics, Reaction Time, Sound, Time Factors, Vibration, Visual Perception, Young Adult, Acoustic Stimulation methods, Attention, Auditory Pathways physiology, Cues, Sound Localization, Speech Perception
- Abstract
Using a well-established binaural-listening paradigm the ability to intentionally switch auditory selective attention was examined under anechoic, low reverberation (0.8 s) and high reverberation (1.75 s) conditions. Twenty-three young, normal-hearing subjects were tested in a within-subject design to analyze influences of the reverberation times. Spoken word pairs by two speakers were presented simultaneously to subjects from two of eight azimuth positions. The stimuli consisted of a single number word, (i.e., 1 to 9), followed by either the direction "UP" or "DOWN" in German. Guided by a visual cue prior to auditory stimulus onset indicating the position of the target speaker, subjects were asked to identify whether the target number was numerically smaller or greater than five and to categorize the direction of the second word. Switch costs, (i.e. reaction time differences between a position switch of the target relative to a position repetition), were larger under the high reverberation condition. Furthermore, the error rates were highly dependent on reverberant energy and reverberation interacted with the congruence effect, (i.e. stimuli spoken by target and distractor may evoke the same answer (congruent) or different answers (incongruent)), indicating larger congruence effects under higher reverberation times., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
12. Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
- Author
-
Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, and Wells A
- Subjects
- Global Health, Humans, Scleroderma, Systemic mortality, Survival Rate, Clinical Trials as Topic methods, Disease Management, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial etiology, Lung Diseases, Interstitial therapy, Scleroderma, Systemic complications
- Abstract
Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (SSc-ILD). Large randomized clinical trials in SSc-ILD have provided important information regarding the feasibility, reliability and validity of outcome measures. Forced vital capacity percentage predicted should be considered as a primary outcome measure, with inclusion of appropriate radiological and patient-reported measures. We provide practical recommendations for trial design in SSc-ILD., (© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
13. Organ-sparing treatment of penile cancer with interstitial pulsed-dose-rate brachytherapy.
- Author
-
Seibold J, Strnad V, and Fietkau R
- Subjects
- Adult, Aged, Dose Fractionation, Radiation, Erectile Dysfunction etiology, Humans, Longitudinal Studies, Male, Middle Aged, Organ Sparing Treatments adverse effects, Penis radiation effects, Radiation Injuries etiology, Radiotherapy Dosage, Treatment Outcome, Brachytherapy adverse effects, Brachytherapy methods, Erectile Dysfunction prevention & control, Organ Sparing Treatments methods, Penile Neoplasms radiotherapy, Radiation Injuries prevention & control
- Abstract
Aim: To assess the efficacy and toxicity profile of protocol-based interstitial pulsed-dose-rate (PDR) brachytherapy for penile carcinoma., Patients and Methods: From August 2002 to February 2014, 13 men with penile cancer were treated by interstitial brachytherapy. The tumor stage was T1 for eight patients, T2 for four patients, and T3 for one patient. The tumor grade was well differentiated for five patients and moderately differentiated for seven patients, while it was unknown for one patient. Lymph node staging was positive for three of 13 patients. All patients were treated using interstitial PDR brachytherapy with dose specifications according to the Paris system. For data collection of erectile dysfunction, the International Index of Erectile Function questionnaire was used, supplemented by the follow-up data., Results: The median follow-up was 54.0 months (range, 13-155 months). Only one patient (1/13, 7.7 %) with local failure was documented. At 5 and 10 years, the local cumulative recurrence rate, disease-free survival, and the cancer-specific survival rates were 12.5 % (95 % CI, 80.4-119.6), 80.8 % (95 % CI, 75.2-124.8), and 77.9 % (95 % CI, 74.3-125.7), respectively. At the time of analysis, nine of 13 men were alive; two of 13 men died of distant metastases from the tumor and two for other reasons with no sign of cancer disease. Serious late side effects such as soft tissue necrosis occurred in four of 13 patients (30 %) and all were successfully treated with medication. Mutilating salvage surgery was not necessary in any of the cases. Urethral stenosis was documented for two of 13 (15.4 %) and dysuria occurred in four of 13 patients (30.8 %). Eight of 11 men (72.7 %) never or only sometimes had erectile dysfunction., Conclusion: In selected patients, interstitial PDR brachytherapy of penile cancer is effective as an organ-sparing treatment. It yields satisfactory results for the conservation of sexual function.
- Published
- 2016
- Full Text
- View/download PDF
14. [Not Available].
- Author
-
Seibold J
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.